alexa Clinical Trials On Parkinson?s Disease
ISSN: 2329-6887

Journal of Pharmacovigilance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials
October 27-29, 2014 Hyderabad International Convention Centre, India

Manjunath H
Posters: J Pharmacovigilance
DOI: 10.4172/2329-6887.S1.014
Parkinson?s disease (PD) is a clinical syndrome characterised by combination of rigidity, bradykinesia, tremors, postural instability that can occur for variety of reasons but usually idiopathic. Current available modality of treating for PD are Levodopa, Dopamine receptor agonists, MAO B inhibitors, COMT inhibitors, Apomorphine, Amantidine, Acetylcholine blocking agents and Surgical procedures. Currently, there are two categories of therapies, symptomatic and neuroprotective, which are making their way through the Parkinson?s pipeline. Drugs which entered the market recently are either for use in Parkinson?s or for treating some other conditions, are now being studiedfor treating additional Parkinson?s symptoms like-Rasagiline, Naltrexone (compulsive gambling or shopping), Rivastigmine, Lubiprostone (for alleviating constipation), Donepezil. In the symptomatic therapy category: intraduodenal levodopa, safinamide (MAO inhibitors), istradefylline (adenosine agonist), pimavanserin, and pitolisant are under phase III trials, whereas in the neuroprotective category there are 2 drugs: Coenzyme Q10(CoQ10), and creatine. In Phase II of clinical trials, four symptomatic therapies namely Pardoprunox, Fipamezole, Prosavin (gene therapy), AFQ056 and four neuroprotective drugs namely isradipine (Ca channel blocker), CERE- 120 (AAV neurturin), urate and PYM50028 are under study. Drugs targeting proteins produced by genes alphasynuclein and LRRK2, drugs reducing inflammation in the brain, use of growth factors and neuroregenerative approach are few of the neuroprotective strategies which are in preclinical discovery phase. Drugs most likely to emerge soon from the pipeline are symptomatic treatment drugs that have been studied the longest (in Phase II and Phase III trials). Within about three years, the hope is that modestly effective neuroprotective therapies -CoQ10, creatine or isradipine will be approved. While we can?t say now exactly what?s next, we can be optimistic at the level and type of research ongoing for Parkinson?s, all of whichaims to improve and perhaps more importantly, reverse the course of Parkinson?s for all of those living with the disease.
Manjunath H has completed his MBBS from SS Institute of Medical science and Research Centre, Davangere and is now pursuing his PG In Pharmacology in JJM Medical Davangere. At present he is involved in three research paper.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version